

**LUPIN**

March 5, 2012

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards receipt of final USFDA approval from for the Company's Generic Geodon® Ziprasidone Hydrochloride Capsules, 20 mg, 40 mg, 60 mg and 80 mg strengths.

This may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For LUPIN LIMITED

For **R. V. SATAM**
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: a/a

**LUPIN**

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------	------------	------------------	-------------------

Lupin launches Generic Geodon® Capsules
Receives final FDA Approval for its Generic Geodon® Capsules

Mumbai / Baltimore, March 03, 2012: Pharma major, Lupin Ltd., announced today that it has received final approval for its Ziprasidone Hydrochloride Capsules, 20 mg, 40 mg, 60 mg and 80 mg strengths from the U.S. Food and Drug Administration (FDA).

Lupin's Ziprasidone Hydrochloride Capsules are the AB rated generic equivalent of Pfizer Inc.'s Geodon® capsules. Lupin has already commenced shipping product.

Geodon® capsules are an atypical antipsychotic and are indicated for Schizophrenia. Pfizer's Geodon® capsules had sales of USD 1.35 billion as per IMS Health, December 2011. Lupin was one of the first applicants to file an ANDA for Geodon® Ziprasidone Hydrochloride Capsules, 20 mg, 40 mg, 60 mg and 80 mg strengths and is entitled to shared exclusivity.

Commenting on the approval, Mr. Nilesh Gupta, Group President and Executive Director, Lupin said, "We are very happy to receive this approval. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price".

About Lupin Limited

Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million (USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively. Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

About Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is committed to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

For more information, please contact:

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:

Ph: +91 98 20 338 555

Email: shamshergorawara@lupinpharma.com

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

**Ceodun[®] capsules are a registered trademark / copyright of Pfizer Inc.*